Key result
A shorter duration of dual antiplatelet therapy is noninferior to traditional 12-month DAPT in acute coronary syndrome patients, reducing the risk of major bleeding complications.
Why the study?
Conflicting results have been reported regarding the optimum duration of DAPT in ACS patients, and recent randomized trials in this setting warrant a reconsideration of practice and guidelines.
Does a shorter duration of DAPT reduce major bleeding complications without increasing thrombotic risk compared to traditional 12-month DAPT in ACS patients?
Does a shorter duration of DAPT reduce major bleeding complications without increasing thrombotic risk compared to traditional 12-month DAPT in ACS patients?
Answers are grounded in this paper and cite their sources.
A shorter duration of DAPT may be noninferior to traditional 12-month DAPT in ACS patients, reducing major bleeding complications and prompting a reconsideration of current guidelines.
Conflicting results have been reported so far in pooled analyses and studies evaluating the optimum duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. However, randomized clinical trials dedicated to this specific setting of higher thrombotic risk patients have only recently been completed, pointing at the noninferiority of a shorter strategy as compared to the traditional 12-month DAPT, furthermore allowing to reduce the risk of major bleeding complications. Therefore, a reconsideration of current clinical practice and guidelines should be certainly be advocated in light of the most recent updates, especially among ACS patients treated with percutaneous coronary intervention (PCI) and modern drug-eluting stents (DES). Our aim was to provide a comprehensive review of the available evidence on the optimal DAPT duration in ACS patients.
No takes yet. Share an insight, caveat, or question.
Verdoia et al. (2020) conducted a review in Acute Coronary Syndrome (ACS). Shorter duration dual antiplatelet therapy (DAPT) vs. Traditional 12-month DAPT was evaluated. A shorter duration of dual antiplatelet therapy is noninferior to traditional 12-month DAPT in acute coronary syndrome patients, reducing the risk of major bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: